Short answer
AGIOS PHARMACEUTICALS, INC. (AGIO) filed its Q3 2026 10-Q quarterly report on Nov 5, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $55M (up 330.0% year over year) with net income of −$65M.
Q3 2026 key financials · XBRL
- Revenue
- $55M
- +330.0% YoY · +23.8% QoQ
- Net income
- −$65M
- +37.1% YoY · +35.4% QoQ
- Operating margin
- -139.3%
- EPS (diluted)
- −$1.08
- +39.3% YoY · +36.1% QoQ
Source: XBRL data from the AGIOS PHARMACEUTICALS, INC. (AGIO) Q3 2026 10-Q on SEC EDGAR. USD.
AGIOS PHARMACEUTICALS, INC. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Q3 revenue $55.4M, up $42.5M YoY from $12.9M, driven by AQVESME® sales
- Net loss $65.0M vs $103.4M YoY, with operating expenses $132.5M vs $129.7M
- Best-performing line: U.S. product revenue $48.7M vs $12.3M, driven principally by AQVESME®
- Cash, equivalents and marketable securities $907.0M; operating cash outflow $235.5M for nine months
- PDUFA date for mitapivat in SCD extended to February 1, 2027; potential headwinds include increased commercialization costs and further capital needs
Risk Factors
- New legal risk: Annora’s April 17, 2026 Paragraph IV challenge to PYRUKYND® patents triggered infringement litigation filed May 26, 2026
- Regulatory risk: FDA requested mitapivat SCD REMS information, extending the PDUFA goal date to February 1, 2027
- Operational risk: AQVESME® commercialization depends on REMS compliance, with FDA enforcement possible for failures by Agios or its service provider
- Competitive risk: Generic PYRUKYND® entry could follow patent litigation, although FDA approval is stayed until at least August 17, 2029
- Financial risk: Nine-month 2026 net loss reached $264.9 million, with accumulated deficit of $826.6 million as of September 30, 2026
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other AGIOS PHARMACEUTICALS, INC. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.